Breaking News

Takeda Launches Subsidiary in Peru

August 23, 2013

Orrego to lead operations

Takeda Pharmaceuticals International GmbH has further expanded its presence in Latin America with the launch of a wholly owned subsidiary in Lima Peru, Takeda Peru S.R.L., which will be responsible for the sales and marketing of Takeda's products in the country.
Takeda Peru is building a product portfolio based on local need, focusing on gastroenterology, cardiology, metabolism, oncology and respiratory diseases. The company will initially focus on Zurcal (pantoprazole), Riopan (Magaldrate + Dimeticone) Faktu (Policresulen, Cinchocaine hydrochloride), and Albothyl (Policresulen).
Julio Cesar Acevedo Orrego has been appointed country manager for Peru. He joins the company from Takeda Colombia, where he headed the Takeda sales and marketing organization following the acquisition of Farmacol Laboratories. He will lead the start-up team, which will grow as the company expands its portfolio and enters new therapeutic areas.
"The launch of our subsidiary in Peru reinforces Takeda's position in Latin America and will enable us to meet the diverse healthcare needs of the population. We have an established product portfolio that will give us a strong starting point, and we look forward to launching our novel medicines into the market," said Norbert Oppitz, senior vice president, Latin America, at Takeda. "This investment further demonstrates our commitment to Latin America and its growth potential."
Takeda also has a presence in Brazil, Mexico, Argentina, Venezuela, Colombia, and Ecuador, and is looking at opportunities to further expand in the region. According to IMS Market Prognosis, pharmaceutical sales in these countries totaled $60 billion in 2012 and are expected to grow at a compound annual rate of 12.5% between 2013 and 2017.

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research